Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: LABORATOIRE HRA PHARMA, 200 avenue de Paris, 92320, CHATILLON, France
Pharmacotherapeutic group: Sex hormones and modulators of the genital system, emergency contraceptives
ATC code: G03AD02
Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor. When used for emergency contraception the mechanism of action is inhibition or delay of ovulation via suppression of the luteinising hormone (LH) surge. Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days in 78.6% of cases (p<0.005 vs. levonorgestrel and vs. placebo) (see table).
Prevention of ovulation1,§:
| Placebo n=50 | Levonorgestrel n=48 | Ulipristal acetate n=34 | |
|---|---|---|---|
| Treatment before LH surge | n=16 0.0% | n=12 25.0% | n=8 100% p<0.005* |
| Treatment after LH surge but before LH peak | n=10 10.0% | n=14 14.3% NS† | n=14 78.6% p<0.005* |
| Treatment after LH peak | n=24 4.2% | n=22 9.1% NS† | n=12 8.3% NS* |
1 Brache et al, Contraception 2013
§ defined as presence of unruptured dominant follicle five days after late follicular-phase treatment
* compared to levonorgestrel
NS: non statistically significant
† compared to placebo
Ulipristal acetate also has high affinity for the glucocorticoid receptor and in vivo, in animals, antiglucocorticoid effects have been observed. However, in humans, no such effect has been observed even after repeat administration at the daily dose of 10 mg. It has minimal affinity to the androgen receptor and no affinity for the human estrogen or mineralocorticoid receptors.
Results from two independent randomised controlled trials (see Table) showed the efficacy of ulipristal acetate to be non-inferior to that of levonorgestrel in women who presented for emergency contraception between 0 and 72 hours after unprotected intercourse or contraceptive failure. When the data from the two trials were combined via meta- analysis, the risk of pregnancy with ulipristal acetate was significantly reduced compared to levonorgestrel (p=0.046).
| Randomised controlled trial | Pregnancy rate (%) within 72h of unprotected intercourse or contraceptive failure2 | Odds ratio [95% CI] of pregnancy risk, ulipristal acetate vs levonorgestrel2 | |
|---|---|---|---|
| Ulipristal acetate | Levonorgestrel | ||
| HRA2914-507 | 0.91 (7/773) | 1.68 (13/773) | 0.50 [0.18-1.24] |
| HRA2914-513 | 1.78 (15/844) | 2.59 (22/852) | 0.68 [0.35-1.31] |
| Meta-analysis | 1.36 (22/1617) | 2.15 (35/1625) | 0.58 [0.33-0.99] |
2 Glasier et al, Lancet 2010
Two trials provide efficacy data on ellaOne used up to 120 hours after unprotected intercourse. In an open-label clinical trial, which enrolled women who presented for emergency contraception and were treated with ulipristal acetate between 48 and 120 hours after unprotected intercourse, a pregnancy rate of 2.1% (26/1241) was observed. In addition, the second comparative trial described above also provides data on 100 women treated with ulipristal acetate from 72 to 120 hours after unprotected intercourse, in whom no pregnancies were observed.
Limited and inconclusive data from clinical trials suggest a possible trend for a reduced contraceptive efficacy of ulipristal acetate with high body weight or BMI (see section 4.4). The meta-analysis of the four clinical studies conducted with ulipristral acetate presented below excluded women who had further acts of unprotected intercourse.
| BMI (kg/m²) | Underweight 0-18.5 | Normal 18.5-25 | Overweight 25-30 | Obese 30- |
|---|---|---|---|---|
| N total | 128 | 1866 | 699 | 467 |
| N pregnancies | 0 | 23 | 9 | 12 |
| Pregnancy rate | 0.00% | 1.23% | 1.29% | 2.57% |
| Confidence interval | 0.00–2.84 | 0.78–1.84 | 0.59–2.43 | 1.34-4.45 |
A post-marketing observational study evaluating efficacy and safety of ellaOne in adolescents aged 17 and younger showed no difference in the safety and efficacy profile compared to adult women aged 18 and older.
Following oral administration of a single 30 mg dose, ulipristal acetate is rapidly absorbed, with a peak plasma concentration of 176 ± 89 ng/ml occurring approximately 1 hour (0.5-2.0 h) after ingestion, and with an AUC0-∞ of 556 ± 260 ng.h/ml.
Administration of ulipristal acetate together with a high-fat breakfast resulted in approximately 45% lower mean Cmax, a delayed Tmax (from a median of 0.75 hours to 3 hours) and 25% higher mean AUC0-∞ compared with administration in the fasted state. Similar results were obtained for the active mono-demethylated metabolite.
Ulipristal acetate is highly bound (>98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, and high density lipoprotein.
Ulipristal acetate is a lipophilic compound and is distributed in breast milk, with a mean daily excretion of 13.35 µg [0-24 hours], 2.16 µg [24-48 hours], 1.06 µg [48-72 hours], 0.58 µg [72-96 hours], and 0.31 µg [96-120 hours].
In vitro data indicate that ulipristal acetate may be an inhibitor of BCRP (Breast Cancer Resistance Protein) transporters at the intestinal level. The effects of ulipristal acetate on BCRP are unlikely to have any clinical consequences.
Ulipristal acetate is not a substrate for either OATP1B1 or OATP1B3.
Ulipristal acetate is extensively metabolised to mono-demethylated, di-demethylated and hydroxylated metabolites. The mono-demethylated metabolite is pharmacologically active. In vitro data indicate that this is predominantly mediated by CYP3A4, and to a small extent by CYP1A2 and CYP2A6. The terminal half-life of ulipristal acetate in plasma following a single 30 mg dose is estimated to 32.4 ± 6.3 hours, with a mean oral clearance (CL/F) of 76.8 ± 64.0 L/h.
No pharmacokinetic studies with ulipristal acetate have been performed in females with impaired renal or hepatic function.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity. Most findings in general toxicity studies were related to its mechanism of action as a modulator of progesterone and glucocorticoid receptors, with antiprogesterone activity observed at exposures similar to therapeutic levels.
Information from reproductive toxicity studies is limited due to the absence of exposure measurement in these studies. Ulipristal acetate has an embryolethal effect in rats, rabbits (at repeated doses above 1 mg/kg) and in monkeys. At these repeated doses, the safety for a human embryo is unknown. At doses which were low enough to maintain gestation in the animal species, no teratogenic effects were observed.
Carcinogenicity studies (in rats and mice) showed that ulipristal acetate is not carcinogenic.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
